Controlled release of interleukin-2 for tumour immunotherapy using alginate/chitosan porous microspheres

Journal of Controlled Release

Volumn 43, Issue 1, 1997, Pages 65-74

  Liu, Lin Shu ^a   Liu, Shu Qin ^b   Ng, Steven Y ^a   Froix, Michael ^a   Ohno, Tadao ^b   Heller, Jorge ^a  

^a Advanced Polymer Systems   (United States)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Alginate; Chitosan; Controlled delivery; Immunotherapy; Interleukin

Indexed keywords

ALGINIC ACID; CALCIUM CHLORIDE; CHITOSAN; INTERLEUKIN 2; MICROSPHERE; POLYLYSINE;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FREEZE DRYING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031060250     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01471-X     Document Type: Article

References (30)

1. E.A. Clark and J.A. Ledbetter, How B and T cells talk to each other. Nature 367 (1994) 425-428.
2. F. Powrie and R.L. Coffman, Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol. Today 14 (1993) 270-274.
3. S.A. Rosenberg, Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat. Rep. 68 (1984) 233-255.
4. S.A. Rosenberg, M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, C.A. Seipp, C. Simpson and C.M. Reichert, Observations on the systemic adminstration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med. 313 (1985) 1485-1492.
5. S.A. Rosenberg, M.T. Lotze, L.M. Muul, A.E. Chang, F.P. Avis, S. Leitman, M. Linehan, C.N. Robertson, R. Lee, J.T. Rubin, C.A. Seipp, C.G. Simpson and D.E. White, A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Eng. J. Med. 316 (1987) 789-897.
6. R.I. Fisher, C.A. Coltman Jr, J.H. Doroshow, A.A. Rayner, M.J. Hawkins, J.W. Mier, P. Wiernik, J.D. McMannis, G.R. Weiss, K.A. Margolin, B.T. Gemlo, D.F. Hoth, D.R. Parkinson and E. Paietta, Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Annals Internal. Med. 108 (1988) 518-525.
7. P.K. Wallace, L.D. Palmer, D. Perry-Lalley, E.S. Bolton, R.B. Alexander, P.K. Horan, J.C. Yang and K.A. Muirhead, Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res. 53 (1993) 2358-2367.
8. Y. Kawakami, S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki and S.A. Rosenberg, Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91 (1994) 6458-6462.
9. S.Q. Liu, R. Shiba, B.S. Kim, K. Saijo and T. Ohno, Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells. Cancer Immunol. Immunother. 39 (1994) 279-285.
10. S.L. Topalian, D. Solomon and S.A. Rosenberg, Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142 (1989) 3714-3725.
11. T. Wolfel, W. Herr, P. Coulie, U. Schmitt, K.-H.M. Buschenfelde and A. Knuth, Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T lymphocyte (CTL) clones. Int. J. Cancer 54 (1993) 636-644.
12. S.Q. Liu, K. Saijo, K. Todoroki and T. Ohno, Induction of human autologous cytotoxic T lymphocytes on formalin-fixed paraffin embedded tumour sections. Nature Med. 1 (1995) 267-271.
13. R.I. Fisher, C.A. Coltman et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Annals Inter. Med. 108 (1988) 518-523.
14. T. Nishimura, Y. Togashi, M. Goto, H. Yagi, Y. Uchiyama and Y. Hishimoto, Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly recombinant interleukin-2. Cancer Immunol. Immunother. 21 (1986) 12-18.
15. J.H. Donohue and S.A. Rosenberg, The fate of interleukin-2 after in vivo administration. J. Immunol. 130 (1983) 2203-2208.
16. K. Morikawa, F. Okada, M. Kosokawa and H. Kobayashi, Enhancement of therapeutic effects of recombinant interleukin-2 on a transplantable rat fibrosarcoma by use of a sustained release vehicle, pluronic gel. Cancer Res. 47 (1987) 37-41.
17. J.R. Deloach, K. Andrews and C.L. Sheffield, Encapsulation of interleukin-2 in murine erythrocytes and subsequent deposition in mice receiving a subcutaneous injection. Biotech. Appl. Biochem. 10 (1988) 183-190.
18. M.S. Hora, R.K. Rana, J.H. Nunberg, T.R. Tice, R.M. Gilley and M.E. Hudson, Controlled release of interleukin-2 from biodegradable microspheres. Biotechnology 8 (1990) 755-758.
19. T.W. Atkins, R.L. McCallion and B.J. Tighe, The incorporation and release of glucose oxidase and interleukin-2 from a bead formed macroporous hydrophilic polymer matrix. J. Biomater. Sei. Polymer Edn. 6 (1994) 651-659.
20. C.K. Kim and E.J. Lee, The controlled release of blue dextran from alginate beads. Int. J. Pharm. 79 (1992) 11-19.
21. O.N. Singh and D.J. Burgess, Characterization of albumin-alginic acid complex coacervation. J. Pharm. Pharmacol. 41 (1989) 670-673.
22. E.C. Downs, N.E. Robertson, T.L. Riss and M.L. Plunkett, Calcium alginate beads as slow-release system for delivering angiogenic molecules in vivo and in vitro. J. Cell Phys. 152 (1992) 422-429.
23. E.R. Edelman, E. Mathiowitz, R. Langer and M. Klagsbrun, Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12 (1991) 619-625.
24. R.J. Mumper, A.S. Hoffman, P.A. Puolakkainen, L.S. Bouchard and W.R. Gombotz, Calcium-alginate beads for the oral delivery of transforming growth factor-b1 (TGF-b1): stabilization of TGF-b1 by the addition of polyacrylic acid within acid-treated beads. J. Control. Release 30 (1994) 241-251.
25. P.A. Sandford and G.P. Hutchings, in: M. Yalpani (Ed.) Industrial polysaccharides, genetic engineering, structure/ property relations and applications, Elsevier, Amsterdam, 1987, pp. 363-376.
26. M.M. Daly and D. Knorr, Chitosan-alginate complex coacervate capsules: effects of calcium chloride, plasticizers, and polyelectrolytes on mechanical stability. Biotech. Progr. 4 (1988) 76-81.
27. K. Suzuki, A. Tokoro, Y. Okawa. S. Suzuki and M. Suzuki, Effect of N acetychito oiligosaccharides on activation of phagocytes. Microbiol. Immunol. 30 (1986) 777-787.
28. C.-S. Hsieh, A.B. Heimberger, J.S. Gold, A. O'Garra and K.M. Murphy, Differential regulation of T helper phenotype development by interleukin 4 and 10 in an ab T-cell-recepter transgenic system. Proc. Natl. Acad. Sci. USA 89 (1992) 6065-6069.
29. J.R. Nixon, in: U.V. Banaker (Ed.) Pharmaceutical dissolution testing, Marcel Dekker, Inc., New York, 1991, pp. 94-96.
30. A.L. Dainty, K.H. Gouldin, P.K. Robinson, I. Simpkins and M.D. Trevan, Stability of alginate-immobilized algal cells. Biotech. Bioeng. 28 (1986) 210-216.